In this episode of #AskDrDurie, IMF Co-Founder and Chairman Dr. Brian G.M. Durie answers a patient submitted question regarding receiving an initial diagnosis of standard myeloma, having treatment, and then being told the myeloma was high risk. He explains when and why that can happen and discusses different kinds of testing involved.

 


Image of Dr. Brian G.M. DurieDr. Brian G.M. Durie serves as Chairman of the International Myeloma Foundation and serves on its Scientific Advisory Board. Additionally, he is Chairman of the IMF's International Myeloma Working Group, a consortium of nearly 200 myeloma experts from around the world. Dr. Durie also leads the IMF’s Black Swan Research Initiative®.

 

Previous Post
#AskDrDurie: Should I have an ASCT if I've been through therapy and am in remission?
Next Post
#AskDrDurie: Can a low white blood cell count be enough to trigger a need for myeloma therapy?

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.